Among the GLP-1 RA outcome trials, only AMPLITUDE-O showed significant reduction in risk of heart-failure-related hospitalisations with a hazard ratio of 0.61 (95% CI [0.38, 0.98]) [59]. This evidence concerns the gene GLP1R and heart failure.